Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In‐depth sinus surgery analysis von Fokkens, Wytske J., Mullol, Joaquim, Kennedy, David, Philpott, Carl, Seccia, Veronica, Kern, Robert C., Coste, André, Sousa, Ana R., Howarth, Peter H., Benson, Victoria S., Mayer, Bhabita, Yancey, Steve W., Chan, Robert, Gane, Simon B.

Volltext

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions von Gibson, Peter G., Prazma, Charlene M., Chupp, Geoffrey L., Bradford, Eric S., Forshag, Mark, Mallett, Stephen A., Yancey, Steve W., Smith, Steven G., Bel, Elisabeth H.

Volltext

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis von Wechsler, Michael E, Akuthota, Praveen, Jayne, David, Khoury, Paneez, Klion, Amy, Langford, Carol A, Merkel, Peter A, Moosig, Frank, Specks, Ulrich, Cid, Maria C, Luqmani, Raashid, Brown, Judith, Mallett, Stephen, Philipson, Richard, Yancey, Steve W, Steinfeld, Jonathan, Weller, Peter F, Gleich, Gerald J

Volltext

Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count von Bachert, Claus, Sousa, Ana R., Han, Joseph K., Schlosser, Rodney J., Sowerby, Leigh J., Hopkins, Claire, Maspero, Jorge F., Smith, Steven G., Kante, Oliver, Karidi-Andrioti, Despina E., Mayer, Bhabita, Chan, Robert H., Yancey, Steve W., Chaker, Adam M.

Volltext

Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine von Pavord, Ian D., Menzies-Gow, Andrew, Buhl, Roland, Chanez, Pascal, Dransfield, Mark, Lugogo, Njira, Keene, Oliver N., Bradford, Eric S., Yancey, Steve W.

Volltext

Update on immunogenicity in severe asthma: Experience with mepolizumab von Ortega, Hector G., Meyer, Erik, Brusselle, Guy, Asano, Koichiro, Prazma, Charlene M., Albers, Frank C., Mallett, Stephen A., Yancey, Steve W., Gleich, Gerald J.

Volltext

Controller medications and their effects on asthma exacerbations temporally associated with upper respiratory infections von Prazma, Charlene M, Kral, Kenneth M, Gul, Nadeem, Yancey, Steve W, Stempel, David A

Volltext

Evaluating treatment response to mepolizumab in patients with severe CRSwNP von Hopkins, Claire, Han, Joseph K., Lund, Valerie J., Bachert, Claus, Fokkens, Wytske J., Diamant, Zuzana, Mullol, Joaquim, Sousa, Ana R., Smith, Steven G., Yang, Shibing, Mayer, Bhabita, Yancey, Steve W., Chan, Robert H., Lee, Stella E.

Volltext

One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma von Stempel, David A., Meyer, Jay W., Stanford, Richard H., Yancey, Steve W.

Volltext

Mepolizumab for chronic rhinosinusitis with nasal polyps : treatment efficacy by comorbidity and blood eosinophil count von Bachert, Claus, Sousa, Ana R, Han, Joseph K, Schlosser, Rodney J, Sowerby, Leigh J, Hopkins, Claire, Maspero, Jorge F, Smith, Steven G, Kante, Oliver, Karidi-Andrioti, Despina E, Mayer, Bhabita, Chan, Robert H, Yancey, Steve W, Chaker, Adam M

Volltext

VARIABILITY OF ASTHMA SYMPTOM BURDEN AMONG CHILDREN: AN OBSERVATIONAL STUDY von DiSantostefano, Rachael L., Davis, Kourtney J., Frytak, Jennifer R., Yancey, Steve W., Guilbert, Theresa W.

Volltext

The effectiveness of fluticasone propionate/salmeterol 100/50mcg diskus(R) (FSC) as an inhaled corticosteroid-sparing agent: Effect of baseline asthma severity von Dorinsky, Paul M, Yancey, Steve W, Reilly, Donna, Edwards, Lisa

Volltext

The Effectiveness of Fluticasone Propionate/Salmeterol 100/50mcg Diskus® (FSC) as an Inhaled Corticosteroid-Sparing Agent: Effect of Baseline Asthma Severit von Dorinsky, Paul M., Yancey, Steve W., Reilly, Donna, Edwards, Lisa

Volltext

Clinical markers of worsening asthma with the fluticasone propionate/salmeterol 100/50mcg diskus(R) (FSC) vs fluticasone propionate (FP) 250mcg alone in patients requiring FP 250 m... von Dorinsky, Paul M, Yancey, Steve W, Waitkus-Edwards, Kelli, Edwards, Lisa

Volltext

Clinical Markers of Worsening Asthma With the Fluticasone Propionate/Salmeterol 100/50 mcg Diskus® (FSC) vs Fluticasone propionate (FP) 250 mcg Alone in Patients Requiring FP 250 m... von Dorinsky, Paul M., Yancey, Steve W., Waitkus-Edwards, Kelli, Edwards, Lisa

Volltext

SON drives oncogenic RNA splicing in glioblastoma by regulating PTBP1/PTBP2 switching and RBFOX2 activity von Kim, Jung-Hyun, Jeong, Kyuho, Li, Jianfeng, Murphy, James M., Vukadin, Lana, Stone, Joshua K., Richard, Alexander, Tran, Johnny, Gillespie, G. Yancey, Flemington, Erik K., Sobol, Robert W., Lim, Ssang-Teak Steve, Ahn, Eun-Young Erin

Volltext

Ester reduction on bifunctional metal-acid catalysts: Effect of metal to acid ratio von Berdugo-Díaz, Claudia E., Manetsch, Melissa T., Lee, Jieun, Sik Yun, Yang, Yancey, David F., Rozeveld, Steve J., Luo, Jing, Chen, Xue, Flaherty, David W.

Volltext

Abstract LB-204: SON controls the oncogenic alternative splicing program in glioblastoma by regulating PTBP1/2 switch and RBFOX2 activity von Kim, Jung-Hyun, Stone, Joshua K., Li, Jianfeng, Richard, Alexander, Vukadin, Lana, Gillespie, G. Yancey, Sobol, Robert W., Lim, Steve, Ahn, Eun-Young Erin

Volltext

In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer von GOLDMAN, C. K, SOROCEANU, L, SMITH, N, GILLESPIE, G. Y, SHAW, W, BURGESS, S, BILBAO, G, CURIEL, D. T

Volltext